Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sab Biotherapeutics Inc. (Sab Bio)
Headquarters: Miami, FL, United States of America
Website: https://www.sab.bio/
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Samuel J. Reich
Number Of Employees: 63
Enterprise Value: $19,049,771
PE Ratio: -0.32
Exchange/Ticker 1: NASDAQ:SABS
Exchange/Ticker 2: N/A
Latest Market Cap: $10,960,900
BioCentury | Jun 1, 2024
Management Tracks
Verve promotes Lister to CSO
Plus: Quantum-Si appoints Kummeth independent chair and updates from Alkeus and SAB
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
BioCentury | Apr 26, 2023
Finance
April 26 Quick Takes: Orbital’s $270M A round is year’s largest so far
Plus: Medicare to cover Leqembi, if approved; Sangamo restructuring; and updates from Roche, GSK, Seres and more
BioCentury | Mar 3, 2022
Deals
March 2 Quick Takes: Sanofi adds mAb masking tech in Adagene deal
Plus NIH ends only active arm in ACTIV-2 and updates from Oculis, Ampio, Inovio, Epsilogen, Lexeo, BlueWillow-Medigen, Epigeneron
BioCentury | Jan 7, 2022
Product Development
ACTIV PPP to deliver more COVID therapy data in 2022
The ACTIV adaptive master protocols are testing a range of COVID-19 therapeutic candidates
BioCentury | Sep 28, 2021
Management Tracks
New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership
Plus: Ocular, Genprex, SAB and more
BioCentury | Sep 25, 2021
Regulation
Sept. 24 Quick Takes: Moderna, J&J next up for FDA’s vaccines panel, CDC’s ACIP
Cue the IPO, plus DMD data, Jasper SPAC, GeNeuro-Northwestern, Everest-AbCellera CinRx newco and more
BioCentury | Jun 11, 2021
Management Tracks
Levy leaves Amgen to launch pandemic preparedness alliance; plus Almirall, Vor, Invitae and SAB
Elliott Levy has stepped down as SVP of R&D strategy and operations at Amgen Inc. (NASDAQ:AMGN) to launch International Readiness to Prevent Infectious Viral Disease (INTREPID) Alliance,
BioCentury | Apr 23, 2021
Product Development
Including SAB’s polyclonal therapy in NIAID COVID study could yield shield against variants
NIH has picked SAB’s antibody therapy as the latest addition to its master protocol trial to treat COVID-19 outpatients. As a polyclonal therapy, SAB-185 could offer greater
BioCentury | Apr 22, 2021
Management Tracks
Ceesay joins Coles’ Cerevel as president; plus updates from Replimune, Perceptive, Antiva, Vera, Patient Square, Zymeworks and more
Items per page:
1 - 10 of 21